Izurieta P - Search Results

1

AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.

Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, Godeaux O, Izurieta P, Vaughn DW. Kosalaraksa P, et al. Among authors: izurieta p. J Infect Dis. 2015 Mar 1;211(5):801-10. doi: 10.1093/infdis/jiu548. Epub 2014 Oct 6. J Infect Dis. 2015. PMID: 25293368 Free PMC article. Clinical Trial.

2

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.

Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Descamps D, et al. Among authors: izurieta p. Hum Vaccin. 2009 May;5(5):332-40. doi: 10.4161/hv.5.5.7211. Epub 2009 May 20. Hum Vaccin. 2009. PMID: 19221517

3

Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.

Nolan T, Izurieta P, Lee BW, Chan PC, Marshall H, Booy R, Drame M, Vaughn DW. Nolan T, et al. Among authors: izurieta p. J Infect Dis. 2014 Dec 1;210(11):1800-10. doi: 10.1093/infdis/jiu359. Epub 2014 Jun 27. J Infect Dis. 2014. PMID: 24973461 Free PMC article. Clinical Trial.

4

Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.

Godeaux O, Izurieta P, Madariaga M, Dramé M, Li P, Vaughn DW. Godeaux O, et al. Among authors: izurieta p. Vaccine. 2015 Apr 27;33(18):2189-95. doi: 10.1016/j.vaccine.2014.07.062. Epub 2014 Jul 30. Vaccine. 2015. PMID: 25090645 Free article. Clinical Trial.

5

Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.

Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Dramé M, Vaughn DW, Schuind A. Izurieta P, et al. Vaccine. 2015 Jun 4;33(24):2800-7. doi: 10.1016/j.vaccine.2015.04.027. Epub 2015 Apr 21. Vaccine. 2015. PMID: 25910919 Free article. Clinical Trial.

6

Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.

Izurieta P, Uy-Aragon MJ, Dramé M, Vaughn DW. Izurieta P, et al. Pediatr Infect Dis J. 2016 Feb;35(2):e35-47. doi: 10.1097/INF.0000000000000968. Pediatr Infect Dis J. 2016. PMID: 26551446 Clinical Trial.

7

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.

Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Verstraeten T, et al. Among authors: izurieta p. Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049. Vaccine. 2008. PMID: 18845199

8

Interpretation of the switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10 in Belgium.

Izurieta P, Breuer T. Izurieta P, et al. Lancet Infect Dis. 2018 Aug;18(8):831-832. doi: 10.1016/S1473-3099(18)30410-9. Epub 2018 Jul 11. Lancet Infect Dis. 2018. PMID: 30001856 No abstract available.

9

Underlying factors in paediatric invasive pneumococcal disease in Belgium.

Izurieta P, Scherbakov M, Vetter V. Izurieta P, et al. Lancet Infect Dis. 2021 Feb;21(2):169-170. doi: 10.1016/S1473-3099(20)30867-7. Lancet Infect Dis. 2021. PMID: 33515517 No abstract available.

10

Recommendation to Take a Holistic View of the Dynamic Pathogenic Pneumococcal Environment.

Izurieta P, AbdelGhany M, Paynter J, Petousis-Harris H. Izurieta P, et al. Clin Infect Dis. 2022 Aug 24;75(1):e1204-e1205. doi: 10.1093/cid/ciac188. Clin Infect Dis. 2022. PMID: 35274677 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page